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ABSTRACT
Acinetobacter baumannii is one of the most frequent nosocomial pathogen capable of 
acquiring resistance to different antimicrobials. The aim of this study was to investigate the
activity of tetracycline, doxycycline and minocycline, the prevalence of tet(A) and tet(B) 
determinants, and the role of efflux pump in tetracycline resistance among the A. baumannii 
clinical isolates. Susceptibility of 98 A. baumannii isolates to tetracyclines was evaluated by 
disk diffusion method. The presence of  active efflux pump was investigated by determination 
of the minimum inhibitory concentration (MIC) of tetracycline using the carbonyl cyanide 
3-chlorophenylhydrazone (CCCP). Polymerase chain reaction (PCR) was performed to 
investigate the presence of tet(A) and tet(B) determinants in tetracycline-resistant isolates. The 
rate of resistance to tetracycline, doxycycline and minocycline was 47.95%, 0%, and 30.61%, 
respectively. Among the 47 tetracycline-resistant isolates, 29.79% were originated from burned 
patients and showed MIC ranging from 128-256 µg/mL with both MIC
50 and MIC90 values of 
256 µg/mL, while 70.21% were from ventilator-associated pneumonia (VAP) patients and 




 of 512 µg/mL and 
1024 µg/mL, respectively. The tet(B) gene was found in 61.7% of tetracycline-resistant 
isolates, while none of the isolates carried the tet(A) gene. CCCP led to 2-128-fold reduction in 
tetracycline MIC of the tested isolates. The results showed that doxycycline and minocycline 
are promising agents for the treatment of A. baumannii infections. This study has also 
revealed the role of efflux activity in the resistance to tetracycline of A. baumannii isolates. 
The emergence of resistance to these agents is likely due to the spread of clones presenting 
with a higher prevalence of resistance determinants.
KEYWORDS: Acinetobacter baumannii. Efflux pump. Tet(A), Tet(B). Tetracycline 
resistance. 
INTRODUCTION
Acinetobacter baumannii is an opportunistic microorganism that has emerged as 
one of the most troublesome pathogens worldwide1,2. This pathogen is responsible 
for severe infections, such as ventilator-associated pneumonia (VAP), bloodstream, 
urinary tract, and wound infections3,4. VAP is the most frequent ICU-acquired 
infection, occurring in 9 to 24% of patients intubated for longer than 48 h5. Even 
more worrisome, the ability of this microorganism to acquire resistance to multiple 
antimicrobial agents makes it difficult to treat under certain clinical conditions, 
especially in critically ill patients. Thus, there are currently only a few antibiotics 
expected to be effective against the severe forms of A. baumannii infections leading 
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to the increment of mortality rates, as well as health care 
costs3.
Due to the continued emergence and spread of 
A. baumannii-resistant strains and a few number of 
therapeutic options, other antibiotics have been analyzed 
for use in clinical practice. Tetracyclines, including 
minocycline and doxycycline, have shown promising 
clinical and microbiological effectiveness for treating 
A. baumannii infections. The successful use oftetracyclines 
in combination with other antibiotics has been reported in 
71.9% of respiratory infections and 87.5% of blood stream 
infections6.
The efflux system, found in many bacterial genera, is 
responsible for reducing the antibiotic accumulation and 
is known as an potent mechanism of drug resistance7,8. 
Efflux pump-encoding genes are carried either by genetic 
elements, e.g., TetA and CmlA systems in resistance to 
tetracycline and chloramphenicol, respectively, or by a 
chromosome, being therefore responsible for acquired 
or intrinsic resistances when they are overexpressed9. 
Similar to other Gram-negative bacteria, the efflux pump 
is a main mechanism involved in resistance to tetracycline 
in A. baumannii8. The most common tetracycline-specific 
efflux pumps are members of the major transporters 
facilitator superfamily (MFS)10. These systems expel 
tetracycline molecules from the inside of cells at the 
expense of a proton. Several Tet efflux pumps from the 
MFS superfamily leading to resistance to tetracycline 
have been acquired by clinical isolates of A. baumannii11. 
Tet(A) and Tet(B) are the most prevalent, with Tet(A) efflux 
conferring resistance to tetracycline but not to minocycline 
or doxycycline and Tet(B) conferring resistance to 
tetracycline and minocycline but not to tigecycline12,13. 
It has also been found that Tet(A) acts sinergically with 
the resistance–nodulation–division (RND) superfamily of 
efflux pumps, such as AdeABC and AdeIJK, serving as an 
important resistance mechanism of resistance to tigecycline 
in A. baumannii14. The tet(B) gene was found in at least 50% 
of tetracycline-resistant A. baumannii isolates and tet(A) in 
14-46%15,16. The genetic basis of these determinants remains 
largely unknown. A partially characterized Tn1721-like 
transposon containing the tet(R) and tet(A) genes, encoding, 
a regulatory protein and a resistance protein15, respectively, 
and tet(B) is carried by 5 to 9-kb plasmids in the multidrug 
resistant of A. baumannii17.
In the present study, we investigated (i) the activity 
of tetracycline, doxycycline and minocycline, (ii) the 
prevalence of tet(A) and tet(B) efflux determinants, and 




The present study was approved by the Ethics Committee 
of the Iran University of Medical Sciences, protocol 
Nº IR.IUMS.REC 1395.9221133207. The included patients 
did not directly participate in this study. All experiments 
were performed on bacteria isolated from clinical specimens 
of hospitalized patients. 
Bacterial identification
This cross-sectional study was performed on A. baumannii 
isolates from patients admitted at the burn unit and intensive 
care unit (ICU) of two hospitals, Shahid Motahari and Rasoul 
Akram, in Tehran, Iran, from 2016 to 2017. Each isolate was 
recovered from a particular patient, and only one sample was 
taken from each patient. The standard microbiological and 
biochemical tests, such as Gram staining, oxidase and catalase 
tests, triple sugar iron (TSI) agar culture, SIM (sulfide, indole, 
motility) agar culture, and oxidation-fermentation (OF) 
media culture (Merck, Darmstadt, Germany) were grown 
at 44 ºC, used in the initial identification of isolates18, and 
then, submitted to PCR-sequencing of blaOXA-51-like gene 
to confirm the isolates as A. baumannii4. This sequencing 
was deposited in GenBank data library with the accession 
number MG920243. All isolates were stored in Luria-Bertani 
broth (Merck Co., Darmstadt, Germany) containing 20% 
glycerol at -70 °C for further use. A. baumannii ATCC® 
19606 (American Type Culture Collection, VA, USA) was 
used as the quality control.
Antimicrobial susceptibility testing
Susceptibility of A. baumannii isolates to three 
tetracyclines (Mast, Merseyside, UK), including tetracycline 
(30 µg), doxycycline (30 µg) and minocycline (30 µg) 
was evaluated by the Kirby-Bauer disk diffusion method 
according to the Clinical and Laboratory Standard Institute 
recommendations10,19. Pseudomonas aeruginosa ATCC® 
27853 (American Type Culture Collection, VA, USA) was 
used as the control.
Detection of active efflux phenotypes
The presence of active efflux systems was investigated 
in tetracycline-resistant isolates. The minimal inhibitory 
concentration (MIC) of tetracycline was determined 
by the agar dilution method before and after treatment 
of the efflux pump inhibitor with carbonylcyanide 
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3-chlorophenylhydrazone (CCCP) (Sigma-Aldrich, Dorset, 
United Kingdom)20,21. The addition of CCCP to Mueller-
Hinton (M-H) agar plates led to increased intracellular 
concentration of the antibiotic, reducing the MIC in isolates 
having any active efflux pumps. Briefly, 50 µg/mL of CCCP 
were added to each M-H agar plates containing 0.5 to 
1024 µg/mL of tetracycline. Then, the MIC of tetracycline 
was determined for all tetracycline-resistant isolates against 
the A. baumannii ATCC 19606® (American Type Culture 
Collection, VA, USA). M-H agar plates with CCCP without 
antibiotic were used as controls. The effect of the efflux pump 
inhibitor was determined by the detection of a 4-fold or higher 
increment in the susceptibility after treatment with CCCP21.
Polymerase chain reaction (PCR)
Genomic DNA was extracted by the boiling method. One 
to three colonies were dissolved in 500 µL of sterile distilled 
water in microtubes, and then placed in a boiling water 
bath at 100 °C for 10 min, and immediately centrifuged at 
12000×g for 5 min. The supernatant containing total DNA 
was stored at -80 ºC until further used. The presence of Tet 
efflux genes, tet(A) and tet(B), was examined in tetracycline-
resistant A. baumannii isolates using the following specific 
primers16. F, 5’-GCGCGATCTGGTTCACTCG-3’ and 
R, 5’-AGTCGACAGYRGCGCCGGC-3’ for tet(A), 
and F, 5’-TACGTGAATTTATTGCTTCGG-3’ and R, 
5’-ATACAGCATCCAAAGCGCAC-3’ for tet(B). PCR 
amplification was performed in a total volume of 25 µL 
containing 12.5 µL of 2×Taq Master Mix RED (Ampliqon, 







, 4 mM MgCl
2
, 0.2% Tween® 20, 0.4 mM of 
each dNTP), 0.05 units/µL Ampliqon Taq DNA polymerase, 
1 µL of 10 pmol of each primer, 1 µL (20 ng) of DNA 
template, and 9.5 µL of sterile distilled water. The thermal 
cycling protocol for PCR of both tet(A) and tet(B) genes 
was as initial denaturation at 94 ºC for 5 min, followed by 
30 cycles of denaturation at 94 ºC for 1 min, annealing at 
57 ºC for 1 min, and extension at 72 ºC for 1 min, with a 
final extension at 72 ºC for 5 min. The PCR products were 
electrophoresed using 1.5% agarose gel with ethidium 
bromide and photographed under UV light.
Statistical data analysis
All obtained data were recorded, edited and entered 
using the SPSS statistic software package, version 18.0 
(SPSS Inc., Chicago, IL, USA). The differences between 
categorical variables, including clinical specimen types, 
antibiotic resistance pattern, and distribution of tet genes 
were compared by the χ2 (chi-square) test. A P-value <0.05 
was considered as statistically significant.
RESULTS
Bacterial isolates and susceptibility testing
A total of 98 isolates of A. baumannii were obtained 
from patients, of which 66.36% (65/98) were from wounds 
and 33.67% (33/98) from respiratory tract infections of 
burned VAP patients, respectively. Doxycycline was the 
most active antibiotic tested, followed by minocycline 
Figure 1 - PCR amplification of tet(A) (a) and tet(B) (b) genes in selected isolates of A. baumannii. M = Molecular weight marker 
Lane; C+ = Positive control, Lanes 1-4: PCR products of the corresponding gene.
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and tetracycline, with susceptibility rates of 96.93% 
(95/98), 71.57% (68/98), and 43.87% (43/98), respectively 
(Table 1). Among the 47 tetracycline-resistant isolates, 
29.79% (14/47) were from burned patients and showed 





 of 256 µg/mL, while 70.21% (33/47) 
were from VAP patients and had MIC ranges ranging from 




 of 512 µg/mL 
and 1024 µg/mL, respectively. Except for doxycycline, 
resistance rates for both, tetracycline and minocycline, 
were significantly higher in VAP isolates than in isolates 
from burns (100% and 87.87% versus 21.53% and 1.53% 
of resistance against tetracycline and minocycline, 
respectively) (p<0.0001) (Table 1). 
Active efflux phenotypes
The MIC of tetracycline in A. baumannii tetracycline-
resistant isolates was tested in the presence of CCCP. In 
the absence of CCCP, MICs ranged from 128-256 µg/mL 
and 32-1024 µg/mL, respectively, in isolates from 
burns and VAP (Table 2). In the presence of CCCP, all 
tested isolates sshowed tetracycline MIC ranging from 
2-128 µg/mL, with a 2-128-fold reduction compared to 
when CCCP was not added. Furthermore, all bacteria grew 
well in M-H agar plates with CCCP but without tetracycline 
(as control), indicating that 50 µg/mL CCCP had no intrinsic 
antibacterial activity.
Detection of tet efflux genes 
PCR results were positive for the tet(B) gene in 61.7% 
(29/47) of tetracycline-resistant isolates, while none of 
the isolates carried the tet(A) gene. In addition, 38.3% of 
A. baumannii tested isolates (18/47) had no genes studied. 
The prevalence of tet(B) gene in burned and VAP isolates 
was 7.14% (1/14) and 84.84% (28/33), respectively 
(p<0.0001).
DISCUSSION
Due to the increased rate of A. baumannii resistance 
to most antimicrobial agents, evaluating the antimicrobial 
susceptibility of “old” antibiotics that are not used as first line 
drugs in clinical practice is of interest. This study showed 
adequate in vitro activity of doxycycline and minocycline 
in burned patients and only of doxycycline in VAP, showing 
promising clinical and microbiological effectiveness of 
tetracyclines either as monotherapy or in combination with 
other agents for the treatment of A. baumannii infections. 
Similarly, previous epidemiological studies reported 
high susceptibility rates of A. baumannii to doxycycline 
Table 2 - Distribution of the tetracycline MICs in 47 tetracycline-resistant A. baumannii before and after treatment with CCCP.
Burn isolates (n= 14) VAP isolates (n= 33)









reduction in the 
presence of 
CCCP









reduction in the 
presence of 
CCCP
8 (57.14%) 128-256 32-128 2-4 10 (30.3%) 32-1024 8-512 2-4
4 (28.57%) 256 32 8 22 (66.67%) 512 64 8
1 (7.14%) 128 4 32 1 (3.03%) 256 16 16
1 (7.14%) 128 1 128 NA NA NA NA
MIC = Minimum inhibitory concentration; VAP = Ventilator-associated pneumonia; CCCP = carbonyl cyanide 3-chlorophenylhydrazone; 
NA = Not applicable.
Table 1 - Susceptibility pattern of 98 A. baumannii isolates against three tetracyclines.
Phenotype
Burned patients isolates (n= 65) VAP patients isolates (n= 33)
No. (%) of susceptibility patterns to No. (%) of susceptibility patterns to
Tetracycline Doxycycline Minocycline Tetracycline Doxycycline Minocycline
Susceptible 43 (66.15) 64 (98.46) 64 (98.46) 0 31 (93.93) 4 (12.12)
Intermediate 8 (12.3) 1 (1.53) 0 0 2 (6.06) 0
Resistant 14 (21.53) 0 1 (1.53) 33 (100) 0 29 (87.87)
VAP = Ventilator-associated pneumonia.
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(100%)22 and minocycline (56%-94.3%)23,24. In contrast, 
tetracycline exhibited no optimal antibacterial activity for 
the use in clinical practice. In a study by Adibhesami et al.23 
the number of minocycline and doxycycline-susceptible 
A. baumannii isolates was significantly higher than the 
number of tetracycline-susceptibleones. Maleki et al.25 
have also found a resistance rate of 18% to doxycycline 
and 19% to minocycline against A. baumannii isolates, 
while 80% of isolates showed resistant to tetracycline. 
Additionally, VAP isolates showed high levels of resistance 
to tetracycline and high resistance rates to both, tetracycline 
and minocycline, in comparison with isolates from burned 
patients. The majority of VAP isolates carried the tet(B) 
gene in comparison with isolates from burned patients. 
Although the clinical outcomes of patients participating in 
the present study were not assessed, VAP infections due to 
A. baumannii have been associated with a high mortality 
rate, prolonged stay in the intensive care unit, and the rapid 
development of antimicrobial resistance to commonly used 
antimicrobials26, indicating the increased risk of more 
serious infections in critically ill patients.
In addition, our study described A. baumannii isolates 
presenting with the efflux pump phenotype in tetracycline-
resistant isolates recovered from burned and VAP patients. 
The results of the present study showed that the MIC 
for 43 of 47 tetracycline-resistant isolates (91.48%) was 
significantly reduced, by 4-16-fold in the presence of the 
efflux pump inhibitor. Similarly, Ardehali et al.27 found 
that CCCP reduced considerably the MIC of 51.25% of 
tigecycline-resistant A. baumannii isolates by 2-4-fold. 
The MICs of isolates resistant to minocycline, doxycycline, 
and tetracycline in the presence of different efflux pump 
inhibitors, such as CCCP, phenyl-arginine-β-naphthylamide, 
1-(1-naphthylmethyl)-piperazine, reserpine, and verapamil 
were significantly reduced28. Consistent with these findings, 
our results revealed that active efflux pumps could be 
involved in the increased rate of resistance to tetracycline 
in A. baumannii. 
tet(A) and tet(B) determinants conferring efflux 
phenotypes of resistance to tetracycline have been known in 
A. baumannii isolates12. The prevalence of tet(B) and tet(A) 
genes have been reported in at least 50% and 14%-46% 
of tetracycline-resistant A. baumannii isolates9. Our study 
showed a high prevalence (61.7%) of tet(B) but not of 
tet(A) gene in tetracycline-resistant isolates. Similarly, 
in two independenpt studies from Iran, Meshkat et al.28 
and Mosavat et al.29 detected the tet(B) determinant in a 
significant percentage of A. baumannii isolates (100% and 
95%, respectively); interestingly, tet(A) was not found in 
any of the isolates. These results were surprisingly different 
from those reported by other studies8,25,30. Importantly, the 
fact that there was neither tet(B) nor tet(A) in some isolates 
in this study indicates that additional genetic determinants 
other than tet genes may play a role in the expression of 
resistance to tetracycline in some of these strains27,31-33. 
In conclusion, doxycycline presented with a good 
activity and minocycline with a moderate activity, being 
promising drugs for the effective treatment of A. baumannii 
infections. In addition, this study revealed that resistance 
to tetracyclines in the studied isolates is mediated by 
active efflux pumps. Since tetracyclines are not routinely 
used to treat Acinetobacter infections, the presence of 
tetracycline-resistant strains is likely due to the spread of 
clones presenting with a higher prevalence of resistance 
determinants. Hygienic surveillance programs and stringent 
infection control strategies are needed to prevent further 
dissemination. 
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